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ABSTRACT
Umbilical cord blood (UCB) provides a rich source of stem cells for transplantation after myeloablative therapy. One
major disadvantage of UCB transplantation is delayed platelet engraftment. We propose to hasten platelet engraft-
ment by expanding the number of megakaryocyte (MK) precursors (CD34/CD41 cells) through cytokine stimulation
within a closed, pre-clinical liquid culture system. Clinical engraftment data suggest a 5- to 10-fold increase in MK
precursors in a UCB unit can accelerate platelet engraftment, so this was our goal. Thirteen UCB samples from
full-term births were Ficoll-separated and frozen for subsequent use. On thawing, the mononuclear cell population
was positively selected for CD34 expression. The cells were cultured in gas-permeable Teflon-coated bags in
serum-free medium containing the following cytokines: recombinant human interleukin-3, recombinant human Flt3
ligand, recombinant human stem cell factor, and recombinant human thrombopoietin. MK lineage cell expansion was
assessed using mononuclear cell count and flow cytometry (CD34/41, CD41, CD34/61, and CD61 expression) on
days 7, 11, and 14. Optimal expansion of CD34/41 and CD41 cells was observed at day 11, with a median 6-fold and
33-fold increase in the starting cell doses, respectively. CD34/61 and CD61 cell expansion at day 11 was 7-fold and
14-fold, respectively. MK precursors can be successfully expanded from CD34 UCB cells in a closed liquid culture
system using interleukin-3, recombinant human Flt3 ligand, recombinant human stem cell factor, and recombinant
human thrombopoietin to a level that should have a clinical impact in the transplantation setting. Our ex vivo
expansion technique needs to be further optimized before it can be used in a pilot UCB transplantation trial.
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INTRODUCTION
Umbilical cord blood (UCB) provides a rich source of stem
cells for hematopoietic reconstitution after myeloablative ther-
apy. One major disadvantage of UCB is delayed engraftment of
platelets, which can lead to hemorrhagic complications, in-
creased platelet transfusion requirements, prolonged hospital-
ization, and alloimmunization. Platelet recovery can occur at a
median of 71 days after transplantation [1], in contrast to a
median of 24 days for allogeneic bone marrow transplant recip-
ients [2], and 10 days for autologous peripheral blood stem cells
(PBSC) recipients [3]. Clinically, ex vivo expansion strategies
have been found to be safe and effective in both PBSC [4,5] and
UCB transplantations [6].
We propose to accelerate platelet engraftment by expanding
the number of megakaryocyte (MK) precursors through cyto-
kine stimulation. From PBSC engraftment data, the threshold
for signiﬁcantly faster platelet engraftment has been reported to
be between 1 and 3  105 CD34/41 cells/kg in the infused stem
cell product [7-9]. Less is known about the characteristics of
UCB stem cells and their engraftment kinetics. In the largest
published series that looked at this subpopulation of cells, pa-
tients received only 4  104 CD34/41 cells/kg, which may
explain their delayed platelet recovery when compared with
recipients of other stem cell sources [10]. Therefore, the goal of
expansion would be a one-half to one-log increase in this infused
cell population. We have previously demonstrated that MK
precursors and stem cells can be expanded from UCB CD34
cells in collagen and small-scale liquid culture experiments [11].
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In these experiments, we increased the scale of the expansion
and conducted it within a closed liquid culture system, which
can be easily adapted for clinical use.
MATERIALS AND METHODS
Cell Source
UCB samples were taken from placentas of women who had
normal full-term pregnancies; the placentas were to be dis-
carded. The institutional review board approved and consent
was obtained for these collections. A volume of 30 to 100 mL
was drained by gravity into a conical tube containing 1000 U of
preservative-free heparin, 1 mL of 5% human albumin (Alpha
Therapeutics, Los Angeles, CA), and 15 mL of Roswell Park
Memorial Institute medium 1640 (Life Technologies, Grand
Island, NY). The UCB was processed within 24 hours, with
most being processed within 4 hours of collection.
Mononuclear Cell Processing
Mononuclear cells (MNCs) were separated from the whole
cord blood by layering over Ficoll-paque (Pharmacia, Uppsala,
Sweden) and centrifuging for 35 minutes at 1200 rpm. Once
separated, the MNCs were resuspended in 10 mL of phosphate-
buffered saline (PBS) and an automated cell count was obtained
by Coulter Counter (Coulter Electronics, Hialeah, FL). The
MNCs were mixed with Tissue Culture-199 (0.6 of total vol-
ume) (Sigma, St. Louis, MO), 5% human albumin (0.2 of total
volume), and dimethyl sulfoxide (0.2 of total volume) on ice for
a total volume of 20 mL. The cell solution was aliquoted into
sterile cryogenic vials (Corning Inc., Corning, NY), placed in a
Nalgene Cryo Freezer Container (Nalge Nunc International,
Naperville, IL) for freezing, and then stored in liquid nitrogen at
70° C.
Before CD34 selection, the vials were taken out of the
freezer and thawed in a 37° C water bath for 5 minutes. The
cells were washed and resuspended in PBS to a total of 30 mL
and 200 L was set aside for ﬂow cytometric analysis. Cell
viability was assessed with trypan blue (Stem Cell Technologies,
Vancouver, Canada) staining using a hemocytometer. The cells
were then washed and resuspended in buffer solution to a vol-
ume of 300 L (buffer consisted of 14 mL of PBS solution, 1
mL of 5% human albumin, and 1000 U of DNAse [ProMega,
Madison, WI]).
CD34 Selection
The MNCs were selected based on their expression of the
CD34 antigen using magnetic-activated cell-sorting technology
(Miltenyi Biotec, Cologne, Germany) according to the manu-
facturer’s recommendations. During this process, the UCB cells
were incubated with mouse anti-human CD34 antibodies in the
presence of human immunoglobulin G as a blocking reagent.
The cells were then incubated with magnetic-activated cell-
sorting microbeads and passed over a column in a magnetic ﬁeld.
The CD34 cells trapped in the column were then eluted with
1 mL of PBS buffer after the column was removed from the
magnetic ﬁeld [12]. The cells were passed through a second
column in the same fashion to increase purity.
Flow Cytometric Analysis
Flow cytometry was performed on both the pre- and post-
selection cell populations using a FACSort ﬂow cytometer
(Becton Dickinson, San Jose, CA) and was analyzed with
CELLQuest software (Becton Dickinson). In addition to CD45/
CD14 and G1/G2 (isotype), CD34 (FITC and PE), AC133-PE,
CD41-PE (gpIIb/IIIa, an MK-speciﬁc marker), and CD61-
FITC (gpIIIa, an earlier MK marker) were examined (monoclo-
nal antibody for AC133 by Miltenyi Biotec; others by Becton-
Dickinson). The mononuclear population was gated for all of
our analyses.
Clinical-Scale Culture of CD34 Cells in a Closed
System
CD34-selected cells were seeded in 35-mL Vuelife Teﬂon
bags (American Fluoroseal Corp., Gaithersburg, MD) in serum-
free liquid medium (StemSpan SFEM by StemCell Technolo-
gies, Vancouver, Canada) at a concentration of 1.0  104 CD34
cells/mL. Cytokines (all from Stem Cell Technologies) were
added to the medium at the following concentrations: recombi-
nant human interleukin-3 (IL-3) (100 ng/mL), recombinant
human stem cell factor (SCF) (50 ng/mL), recombinant human
thrombopoietin (TPO) (50 ng/mL), and recombinant human
Flt3 ligand (Flt3L) (50 ng/mL). The medium was supplemented
with 0.3% human albumin, penicillin (100 U/mL), and strepto-
mycin (50 g/mL). The bags were placed in a 37° C incubator
with ambient O2 (20%), 5% CO2, and 95% humidity. Cul-
tures were observed using an inverted microscope at 2-day
intervals to determine when maximal expansion had occurred.
Assessment of Cultures for Cell Subpopulation
Expansion
At days 7, 11, and 14, the cultures were sampled and a cell
count was obtained using a Coulter Counter. Flow cytometry
was performed with monoclonal antibodies for CD41, CD61,
CD34, and AC133 as described above.. The ﬁnal cell population
for each speciﬁc marker was calculated by multiplying the ﬁnal
MNC count by the percentage of MNCs that express the
marker (as per ﬂuorescence-activated cell sorter analysis). The
MK precursor population was deﬁned as cells co-expressing
CD34 and CD41.
Statistical Analysis
Expansion of cell subpopulations was calculated by dividing
the ﬁnal cell population by the seeding dose expressing the
speciﬁc marker or markers. The magnitude of expansion (or fold
expansion) was calculated by dividing the ﬁnal MNC count by
the seeding MNC dose. The data set contains the values of
several surface markers (Table 1) measured repeatedly, at days 7,
11, and 14, from each of i  1,. . .,13 cord blood samples. The
surface marker values were evaluated graphically using box plots
[13] and plots of the values over time. Regression of each marker
value at days 11 and 14 on its previous values was evaluated using
the following autoregressive linear model. For a given surface
marker, denote by Yj,t the ratio of the percentage of cells having
that marker in the sample evaluated at day t divided by the
corresponding percentage at time 0. We assume that Yj,t 
7311 I[t  11]  11314 I[t  14]  i, where I[A] is the
indicator of the event A, {, 7311, 11314} are the model
regression parameters, and {1,. . .,13} are iid Gaussian residuals
with mean 0 and constant variance. Thus, each Yj,7 has mean
Yi,11 has mean   7311, and Yj,14 has mean   11314.
Additionally, the term 7314 I[t  14] was included in the
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model for AC133 at day 14, and the value of MNCs at day 7 was
included as a predictor of CD34/61 at day 11. All model ﬁts
were carried out using SAS PROC MIXED [14].
RESULTS
CD34 Cell Selection
After thawing, all UCB samples had 90% cell viability.
The median CD34 purity after immunomagnetic bead selection
for all 13 experiments was 84%. Purity was deﬁned as the
percentage of MNCs that expressed CD34.
Liquid Cell Culture Expansion of MK Lineage
Maximum expansion of the MK precursor population in the
13 experiments occurred at day 11 of culture with a 6-fold
increase of CD34/CD41 cells (range: 2 to 41). On day 11 the
overall median expansions of different cell subpopulations were
as follows: CD41 cells 33-fold (range: 4 to 99), CD34/CD61
cells 7-fold (range: 2 to 613), and CD61 cells 14-fold (range: 3
to 104). Expansion of these cell subpopulations at days 7, 11, and
14 are presented in Figure 1 and Table 1. A representative
FACS analysis of CD34 and CD41 expression on day 11 of
culture is demonstrated in Figure 2.
Liquid Cell Culture Expansion of Stem Cells
and MNCs
CD34 cells expanded 6-fold (range: 2 to 54), AC133 cells
expanded 10-fold (range: 1 to 5911), and MNCs expanded
61-fold (range: 6 to 210). Expansion of these cell subpopulations
at days 7, 11, and 14 are presented in Figure 3 and Table 1.
For each of the 6 states of differentiation (AC 133, CD34,
CD41, CD61, CD34/CD41, and CD34/CD61), the expression
level at day 7 was a strong predictor of the level at day 11 (Table
1). The day 11 levels strongly predicted the day 14 levels for
CD34/41 and AC133, with this regression present but weaker
for the other markers. In terms of average behavior, CD34,
CD41, CD61, and AC133 each increased from day 7 to day 11
and then decreased from day 11 to day 14. The MNC levels
showed a monotone increase in both average value and variabil-
ity over time. The greatest overall variability was seen in AC133.
Two of the 13 cases had extreme AC133 values at days 7, 11, and
14, speciﬁcally 4926, 5911, and missing for patient number 3
and 367, 510, and 80 for patient number 8. To assess its sensi-
Table 1. Parameter Estimates of the Fitted Autoregressive Models for
Marker Level
Marker Variable
Estimated
Coefficient (SE) P Value
CD34 Intercept 6.43 (2.72) —
7 3 11 0.55 (0.19) .01
11 3 14 0.21 (0.12) .10
CD34/41 Intercept 7.44 (2.31) —
7 3 11 0.38 (0.14) .01
11 3 14 0.45 (0.10) .00
CD41 Intercept 14.61 (4.25) —
7 3 11 1.70 (0.24) <.0001
11 3 14 0.12 (0.09) .19
CD61 Intercept 16.09 (5.70) —
7 3 11 0.88 (0.14) <.0001
11 3 14 0.11 (0.08) .19
CD34/61 Intercept 24.73 (17.71) —
7 3 11 2.28 (0.21) <.0001
11 3 14 0.09 (0.05) .13
mnc (7) 3 11 0.73 (0.41) .09
AC133 Intercept 495.97 (444.05) —
7 3 11 0.20 (0.004) <.0001
11 3 14 0.68 (0.23) .009
7 3 14 1.82 (0.28) <.0001
AC133 (excluding 1
patient with
AC133 > 4000)
Intercept 48.77 (33.49) —
7 3 11 0.48 (0.08) <.0001
11 3 14 3.24 (0.41) <.0001
7 3 14 3.87 (0.50) <.0001
AC133 (excluding 2
patients with
AC133 > 350)
Intercept 9.95 (3.64) —
7 3 11 0.64 (0.17) .002
11 3 14 0.93 (0.16) <.0001
7 3 14 1.12 (0.20) <.0001
Figure 1. MK lineage expansion in closed liquid culture. Expansion data
presented as fold expansion at days 7, 11, and 14 in culture (13 experi-
ments). Note expansion of all subpopulations peaked at day 11. D
indicates day.
Figure 2. Analysis of CD34 and CD41 expression on a day 11 UCB
liquid culture by 3-color ﬂow cytometry. The cells in the upper left
quadrant represent cells that have been driven toward megakaryocytic
lineage (CD41), the lower right quadrant is the population of expanded,
uncommitted (CD34) stem cells, whereas the upper-right quadrant
represents the MK precursors (CD34/41 co-expression).
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tivity to these extreme values, the autoregressive model for
AC133 was re-ﬁt excluding patient number 3, and then exclud-
ing both patient number 3 and patient number 8. The remaining
11 AC133 paths are shown in Figure 4, which illustrates the
within-sample variability of the pattern of change from day 7 to
day 11 to day 14.
DISCUSSION
One of the greatest obstacles to a safer, more effective, and
economical stem cell transplantation is the delay in platelet
engraftment. Although neutrophil engraftment has been accel-
erated through the use of increased CD34 dosage and/or
granulocyte colony-stimulating factor–primed mobilized stem
cells with posttransplantation administration of granulocyte-
macrophage colony-stimulating factor, little progress has been
made in platelet engraftment. This problem is particularly pro-
nounced in UCB stem cell transplantations. We hypothesize
that by performing transplantations with a stem cell product
enriched for MK precursors we can accelerate the speed of
platelet engraftment. To address this hypothesis, we have been
identifying the optimal combination of cytokines for ex vivo
expansion of MK precursors from CD34 UCB and PBSCs.
Our previous studies in collagen medium and small-scale open
liquid culture wells established that the best combination of
cytokines for expansion was TPO, IL-3, Flt3L, and SCF [11].
CD34-selected cells were chosen as our source of expand-
able cells for several reasons. First, CD34 is one of the earliest
stem cell markers yet identiﬁed, letting us know that we are
growing and differentiating a multipotent cell population. An-
other reason is for the enhanced expandability of this population
when puriﬁed: Briddell et al. showed that unselected UCB cells
incubated with SCF, granulocyte colony-stimulating factor, and
TPO for 10 days multiplied 1.4-fold, whereas CD34 enriched
cells multiplied 113-fold under the same conditions [15]. Our
CD34-selected cells were cultured in a serum-free medium
containing identical concentrations of recombinant human
TPO, IL-3, SCF, and Flt3L, as were used in our earlier exper-
iments. These were contained within a closed, pre-clinical
system that is a larger expansion system based on our ear-
lier, small-scale liquid well culture work. These data suggest
that CD34 selection may eliminate cells that inhibit ex vivo
expansion.
To assess the early megakaryopoietic differentiation of a
cell, we used ﬂow cytometry. We stained our pre- and post-
expanded cell populations with anti-CD61 (glycoprotein IIIa)
monoclonal antibody, the ﬁrst sign of pre-MK development,
and CD41 (glycoprotein IIb/IIIa), a glycoprotein expressed later
in development, but still not indicative of full MK maturation.
We also stained each of these cell populations simultaneously
with anti-CD34 antibody to discern which cells were co-ex-
pressing this stem cell marker and, therefore, were the desired
MK precursor populations.
Calculation of stem cell expansion in our experiments was
performed by dividing the total number of cells expressing the
CD34 marker by the seeding cell dose. In addition to looking at
CD34, we also examined the expression of AC133, a novel early
stem cell marker expressed on a subpopulation of CD34 cells
that may be an indicator of proliferative potential [16,17].
AC133 selection is now being examined for use in ex vivo
expansion [18,19] and retroviral gene transfer experiments [20],
whereas its expression is useful in characterizing malignant cells
[21,22] and normal stem cells [23] and as a predictor of engraft-
ment [24,25].
We have learned from PBSC engraftment data that the
threshold for signiﬁcantly faster platelet engraftment is in the
range of 1 to 3  105 CD34/41 cells/kg [7-9], with the small
body of UCB data on this subject indicating that this stem cell
source contains approximately 1 log less of this subpopulation of
cells [10]. The authors acknowledge that hematopoietic stem
cells from different sources have different properties and en-
graftment kinetics, but the 10-fold smaller number of MK pre-
Figure 4. Statistical analysis of AC133 expansion variability. The y-axis
is fold expansion of the AC133 population of cells at days 7, 11, and 14.
The heavy line indicates the mean, with each box extending from the
25th to the 75th percentile and the whiskers extending to either the most
extreme (minimum or maximum) value or 1.5 the inter-quartile range.
Figure 3. Stem cell and MNC expansion in closed liquid culture.
Expansion data presented as fold expansion at days 7, 11, and 14 in
culture (13 experiments). Note expansion of all subpopulations peaked at
day 11 except MNC. D indicates day; MNC, mononuclear cells.
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cursors in UCB when compared with UCB recipients could
explain the signiﬁcantly delayed platelet engraftment seen in
these latter patients even with a high CD34 cell dose. There-
fore, the goal of ex vivo expansion of UCB to have a clinical
impact on platelet recovery would need to be at least one-half to
1-log increase in this infused MK precursor population.
The data from our experiments demonstrate that the com-
bination of IL-3, Flt3L, SCF, and TPO in a closed serum-free
liquid culture system is effective at expanding CD34/41 co-
expressing MK precursors as well as more mature and immature
cells in the megakaryocytic lineage (CD41, CD34/61, and
CD61 cells). Although MK precursors increased a median of
6-fold at both days 7 and 11, day 11 was chosen as our optimal
day because this was the day that the proliferation of most other
subpopulations peaked (Figures 1 and 3). The only exception
was MNCs, which had better expansion at day 14 (Figure 3).
Although the expansion of MNC, CD34, and AC133 cells
was not a primary goal of our experiments, we were able to
increase the number of these subpopulations, which, when used
clinically, should enhance both neutrophil and long-term en-
graftment [26,27]. The expansion of these cells shows there is no
“steal” phenomenon whereby cells are all driven irreversibly to
one lineage. It also demonstrates that our technique has the
potential to make UCB more applicable as a stem cell source in
larger patients, where the ﬁnite cell dose was the limiting factor
in the past. As far as expansion goals for MK precursors, we have
met them by achieving a half-log to 1-log expansion at day 11.
Such proliferation of the desired precursors is at the threshold of
faster platelet engraftment but ideally would be of an even
greater magnitude to consistently provide more than sufﬁcient
numbers of these cells to make a clinically signiﬁcant difference.
Another issue facing ex vivo expansion research and its
clinical application is the heterogeneity of response to identical
culture conditions seen between stem cell populations from
different donors. Additional studies are needed to better under-
stand sample heterogeneity and how this might be exploited for
clinical applications.
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